Frank LaSaracina has over 30 years of relevant business experience and nearly 25 years in biopharma, Mr. LaSaracina assists clients with their business development, and expansion.
Mr. LaSaracina was Managing Director of Speedel Pharmaceuticals, Inc., the US subsidiary of Speedel Holding, the Basel-based biopharma company that was acquired by Novartis at a value of approximately CHF 1.0 billion in October of 2008 (US $870M).
Mr. LaSaracina has extensive international experience in business development, licensing, strategic planning, and corporate development in the pharmaceutical industry. During his 20 years with Ciba/Novartis he held numerous management positions, first as director of finance in the US and then in various business development positions. In addition, Frank has led complex global project teams in areas of strategic planning, business restructuring and mergers and acquisitions.
Prior to joining Speedel in 2000 as Managing Director of Speedel Pharmaceuticals, Inc., he was vice president with responsibility for marketing, program management, information technology and strategic management while at Hurley Consulting, a contract research organization. Frank is a past trustee of the Oradell Board of Education as well as Newark Beth Israel Hospital and has served as Treasurer of the Biotechnology Council of New Jersey.